Drug Profile

OCU 410

Alternative Names: AAV-RORA; OCU-410; RORA-AAV

Latest Information Update: 17 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Schepens Eye Research Institute
Developer Ocugen
Class Eye disorder therapies; Gene therapies
Mechanism of Action Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I/II Dry age-related macular degeneration

Most Recent Events

03 Mar 2025 Ocugen plans to file MAA and BLA for dry age-related macular degenration in US and EU in 2028
03 Mar 2025 Ocugen plas to initiate a phase III trial in dry age-related macular degeneration in 2026
19 Nov 2024 Efficacy and adverse events data from the phase I/II ArMaDa trial in Geographic atrophy secondary to dry age-related macular degeneration released by Ocugen

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com